1. CCLHD Research Repositories

Matthew Wong

View Statistics Email Alert RSS Feed

Profile

Loading... 2 0 20 0 false
Credit Name
Matthew Wong
Full Name
Wong, Matthew
ORCID
Loading... 3 0 20 0 false

Publications

Results 1-12 of 12 (Search time: 0.004 seconds).

PreviewIssue DateTitleAuthor(s)
129-Mar-2024Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapseTong, Elissa; Horsley, Patrick; Wheeler, Helen; Wong, Matthew ; Venkatesha, Venkatesha; Chan, Joseph; Kastelan, Marina; Back, Michael 
2Jan-2022Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapyJayamanne, Dasantha ; Wong, Matthew ; Back, Michael ; Metz, G.; Wheeler, H.; Cook, R.; Little, N.; Parkinson, J.; Kastelan, M.; Brown, C.
39-Jun-2021Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastomaCook, Theresa A ; Jayamanne, Dasantha ; Wong, Matthew ; Cove, Nicola ; Back, Michael ; Wheeler, H.; Parkinson, J.; Cook, R. J.; Kastelan, M. A.; Brown, C.
4Mar-2020The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade gliomaWong, Matthew ; Jayamanne, Dasantha ; Back, Michael ; Chan, J.; Wheeler, H.; Khasraw, M.; Kastelan, M.; Guo, L.
5Jun-2019Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic gliomaJayamanne, Dasantha ; Wong, Matthew ; Back, Michael ; Back, E.; Kastelan, M.; Khasraw, M.; Brown, C.; Wheeler, H.
6May-2019Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastomaCuncannon, Moire ; Wong, Matthew ; Jayamanne, Dasantha ; Cove, Nicola ; Back, Michael ; Guo, L.; Wheeler, H.
7Apr-2019Pattern of failure in anaplastic glioma patients with an IDH1/2 mutationBack, Michael ; Jayamanne, Dasantha ; Wong, Matthew ; Brazier, D.; Newey, A.; Bailey, D.; Schembri, G.; Hsiao, E.; Khasraw, M.; Kastelan, M.; Brown, C.; Wheeler, H.
8Apr-2019Influence of molecular classification in anaplastic glioma for determining outcome and future approach to managementBack, Michael ; Jayamanne, Dasantha ; Wong, Matthew ; Brazier, D.; Newey, A.; Bailey, D.; Schembri, G; Hsiao, E.; Khasraw, M.; Kastelan, M.; Guo, L.; Clarke, S.; Wheeler, H.
9Oct-2018Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer CentreBack, Michael ; Jayamanne, Dasantha ; Wong, Matthew ; Cove, N.; Wheeler, H.; Khasraw, M.; Guo, L.; Back, J.
10Sep-2017Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centreWong, Matthew ; Kneebone, Andrew ; Itchins, M.; Arena, J.; Nahm, C.B.; Rabindran, J.; Kim, S.; Gibbs, E.; Bergamin, S.; Chua, T.C.; Gill, Anthony J ; Maher, R.; Diakos, C.; Mittal, A.; Hruby, G.; Pavlakis, N.; Samra, J.; Clarke, S.
11Jul-2016Upstream and downstream co-inhibition of mitogen-activated protein kinase and PI3K/Akt/mTOR pathways in pancreatic ductal adenocarcinomaWong, Matthew ; Xue, A.; Baxter, R.C.; Pavlakis, N.; Smith, R.C.
12Jun-2016Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)Wong, Matthew ; Chan, D.L.; Lee, A.; Li, B.T.; Lumba, S.; Clarke, S.J.; Samra, J.; Pavlakis, N.